Saturday, May 21, 2022
No Result
View All Result
Medical Finance
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
No Result
View All Result
Medical Finance
No Result
View All Result
Home Coronavirus

Researchers assess prevalence of SARS-CoV-2 reinfections

by Medical Finance
in Coronavirus
Study: Evidence of SARS-CoV-2 Reinfection: Analysis of 35,000 Subjects and Overview of Systematic Reviews. Image Credit: Corona Borealis Studio/Shutterstock
9
SHARES
99
VIEWS
Share on FacebookShare on Twitter

In a recent study posted on Preprints with The Lancet*, researchers assessed the prevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) reinfections in the Province of Modena, Italy. They also conducted an overview of systematic reviews (SRs) to summarize the existing knowledge.

Study: Evidence of SARS-CoV-2 Reinfection: Analysis of 35,000 Subjects and Overview of Systematic Reviews. Image Credit: Corona Borealis Studio/Shutterstock
Study: Evidence of SARS-CoV-2 Reinfection: Analysis of 35,000 Subjects and Overview of Systematic Reviews. Image Credit: Corona Borealis Studio/Shutterstock

Background

Reinfections have been reported in patients diagnosed with coronavirus disease 2019 (COVID-19) following hospital discharge or even after several weeks of clinical recovery. Factors such as waning antibodies and the emergence of mutant SARS-CoV-2 variants contribute to the development of reinfections. Assessment of the prevalence of reinfections could guide public health decisions and policies for mitigating COVID-19.

About the study

In the present observational study, researchers used the big data analysis approach to evaluate SARS-CoV-2 reinfection rates among residents of the Province of Modena. They also reviewed existing systematic reviews that reported SARS-CoV-2 reinfection, to provide a summary of the existing findings of SARS-CoV-2 reinfection.

The team retrospectively analyzed the reports of the oropharyngeal or nasopharyngeal swab tests that were performed at the Department of Laboratory Medicine of the USL of Modena for molecular research of SARS-CoV-2 ribonucleic acid (RNA) between January 1, 2021, and June 30, 2021. In the studies, RNA from the nasopharyngeal and oropharyngeal swabs was first extracted and subjected to qualitative reverse transcription-polymerase chain reaction (qRT-PCR) tests to generate amplified copies of complementary deoxyribonucleic acid (cDNA).

The authors chose individuals who had initial positive, subsequent negative, and second positive RT-PCR reports. They considered reinfection to occur if the second RT-PCR report was positive after three months of the first report in individuals who were considered to be cured or a positive RT-PCR test performed >45 days post first positive test, accompanied by epidemiological exposure or associated symptoms.

Data analysis was carried out up to February 22, 2022. Data on the status of vaccination of the positively SARS-CoV-2-reinfected individuals were also obtained. Individuals were grouped into the following age groups:  below 14 years, 15 to 29 years, 30 to 49 years, 50 to 69 years, and >70 years.

Additionally, data were searched on the Medline database using keywords such as “COVID-19, “SARS-CoV-2”, and “reinfection” for SRs published between 2020 and 2022. The team also screened the reference lists of potentially eligible SRs. The included SRs reported on the rate of reinfections, mentioned the search strategy, and reported adequate information including the definitions of reinfection and pooled estimates of the total reinfections count. There were no age, study setting, or language restrictions. SRs were excluded if they were of the narrative type, used animal models, or assessed specimens.

Data were obtained from the selected SRs on the following: SR characteristics (year, country, authors); definition for reinfection; study design (cohort, case report); participant characteristics (symptoms, sample size, sex, age); outcomes (reinfection count, period between initial and subsequent infection).

The quality of each SR was determined using the A MeaSurement Tool to Assess Systematic Reviews (AMSTAR) tool. The frequency of SARS-CoV-2 reinfections was evaluated and data were stratified into subgroups based on the vaccination status of individuals. The rate of reinfection was calculated as the proportion of reinfected individuals compared to the number of individuals who were positive in the first test. The overview was based on Cochrane methods and the findings were reported using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist.

Results

During the study period of 18 months, 178,948 individuals underwent RT-PCR, of which, 20% had received a minimum of one COVID-19 vaccine dose before 30 June, particularly individuals aged above 70 years.

Twenty percent of individuals had positive PCR reports, five of which were vaccinated, and the highest viral load was observed in individuals aged 50 to 69 years (23%). Among vaccinated individuals, 5% of them had a positive PCR report.

In the first test, more than 35,000 (20%) individuals were SARS-CoV-2-positive. However, reinfections were reported in only 1,258 (3.5%) patients; the majority were children below 14 years who were unvaccinated and in individuals aged 30 to 49 years (33%), of whom 66% were vaccinated. Reinfections were significantly higher among unvaccinated individuals (1.1%) compared to vaccinated individuals (0.6%).

The time intervals between the initial and subsequent positive RT-PCR reports were 248 days for adults aged above 70 years and 313 days for children below 14 years, indicating that the elderly population was most vulnerable to SARS-CoV-2 reinfections.

A total of 22 SRs were identified in the data search, of which, three were excluded due to their ineligibility. Furthermore, 10 SRs were excluded, and thus, only nine SRs were considered for the overview. Among the selected SRs, five SRs, three SRs, and one SR were of moderate, low, and very low quality, respectively. The nine selected SRs confirmed that SARS-CoV-2 reinfections were rare.

Overall, the study results showed that although prior SARS-CoV-2 infection and vaccination confer protection against reinfections, the risk of reinfections is real, although rare.

*Important notice

Preprints with The Lancet publish preliminary scientific reports that are not peer-reviewed and, therefore, should not be regarded as conclusive, guide clinical practice/health-related behavior, or treated as established information.

Total
0
Shares
Share 0
Tweet 0
Pin it 0
Share 0
Medical Finance

Medical Finance

Related Posts

Study: Serious hospital events following symptomatic infection with Sars-CoV-2 Omicron and Delta variants: an exposed-unexposed cohort study in December 2021 from the COVID-19 surveillance databases in France. Image Credit: PHOTOCREO Michal Bednarek/Shutterstock

Impact of SARS-CoV-2 Omicron and Delta variants on serious hospital events

by Medical Finance
May 21, 2022
0

In a recent study posted to the medRxiv* pre-print server, a team of researchers assessed the differences in risk of...

Study: Clinical manifestations and disease severity of SARS-CoV-2 infection among infants in Canada. Image Credit: Prostock-studio/Shutterstock

Study explores SARS-CoV-2 manifestations and related hospitalization in infants

by Medical Finance
May 21, 2022
0

A study posted to the medRxiv* preprint server examined the clinical manifestations of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)...

Study: Clinical manifestations and disease severity of SARS-CoV-2 infection among infants in Canada. Image Credit: Prostock-studio/Shutterstock

Study explores SARS-CoV-2 manifestations and related hospitalizations in infants

by Medical Finance
May 21, 2022
0

A study posted to the medRxiv* preprint server examined the clinical manifestations of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)...

Study: SARS-CoV-2 neutralization after mRNA vaccination and variant breakthrough infection. Image Credit: Naeblys / Shutterstock.com

Omicron breakthrough boosts neutralization titers a little more than a 3rd COVID vaccine dose

by Medical Finance
May 21, 2022
0

Despite the widespread availability of effective vaccines in many areas of the world, the severe acute respiratory syndrome coronavirus 2...

Study: Geriatric risk factors for serious COVID-19 outcomes among older adults with cancer: a cohort study from the COVID-19 and Cancer Consortium. Image Credit: FamVeld / Shutterstock.com

Risk factors for COVID-19 in older adult patients with cancer

by Medical Finance
May 21, 2022
0

The death and complication rates of the coronavirus disease 2019 (COVID-19) are significantly higher in older persons as compared to...

Study: The Incidence of SARS-CoV-2 Reinfection in Persons With Naturally Acquired Immunity With and Without Subsequent Receipt of a Single Dose of BNT162b2 Vaccine. Image Credit: Mahsun YILDIZ / Shutterstock.com

Single dose of BNT162b2 vaccine after COVID provides 82% reduction in reinfection risk

by Medical Finance
May 21, 2022
0

Due to the rapidly developing body of research, coronavirus disease 2019 (COVID-19) vaccination policies are constantly changing. In fact, several...

Next Post
Study: A virus-specific monocyte inflammatory phenotype is induced by SARS-CoV-2 at the immune–epithelial interface. Image Credit: MIA Studio/Shutterstock

Researchers investigate SARS-CoV-2 specific inflammatory response

IVM-MS2, “The most compact all-in-one IntraVital two-photon microscopy system in the world”

IVM-MS2, “The most compact all-in-one IntraVital two-photon microscopy system in the world”

0 0 votes
Article Rating
Subscribe
Login
Notify of
guest
guest
0 Comments
Inline Feedbacks
View all comments

Support

  • Contact
  • Disclaimer
  • Home
  • Privacy Policy
  • Terms And Conditions

Categories

  • Coronavirus
  • Insights From Industry
  • Interviews
  • Mediknowledge
  • News
  • Thought Leaders
  • Whitepapers

More News

  • Study: Olverembatinib inhibits SARS-CoV-2-Omicron variant-mediated cytokine release. Image Credit: WhiteDragon/Shutterstock
    Scientists identify multi-kinase inhibitors that can effectively block SARS-CoV-2-mediated cytokine release
  • Study: Accelerated identification of disease-causing variants with ultra-rapid nanopore genome sequencing. Image Credit: Dmitry Kovalchuk/Shutterstock
    Study investigates rapid nanopore whole-genome sequencing approach for identifying genetic variants
  • Home
  • Privacy Policy
  • Contact
  • Disclaimer
  • Terms And Conditions

© 2022 Medical Finance - Latest Financial and Business News

No Result
View All Result
  • Interviews
  • Mediknowledge
  • News
  • Insights From Industry
  • Coronavirus
  • Thought Leaders
  • Whitepapers
wpDiscuz
0
0
Would love your thoughts, please comment.x
()
x
| Reply